Long‐term clinical and radiological outcomes of endoscopic ultrasound‐guided radiofrequency ablation of benign insulinomas
Authors' conclusion
EUS-RFA treatment of benign insulinomas provides a long-term complete clinical resolution of hypoglycaemia. A long-term follow-up is essential if residual tumour persists after initial EUS-RFA treatment.
Study context
- Population
- Patients with sporadic benign insulinoma treated by EUS-RFA in a tertiary centre, June 2018–April 2022; 9 women, 2 men, median age 65 years, mean tumour size 11 mm
- Participants
- 11 patients
- Outcome
- Efficacy, safety and recurrence after EUS-RFA
- Follow-up
- Mean 26 months
Methodological detailssingle-centre, tertiary centre, Clinical, biological and imaging follow-up planned at 3, 6, 12 months and then annually
- Single-centre
- Tertiary centre
- Clinical, biological and imaging follow-up planned at 3, 6, 12 months and then annually
Main finding
As reported in the abstract
- Immediate and complete symptomatic and biological remission in all patients
- 11
- Complete radiological resolution of the tumour
- 7 patients
- Persistence of an asymptomatic tumour residue
- 4 patients
- Significant but asymptomatic increase of the tumour residue
- 2 patients
- Second EUS-RFA session performed
- 1 patient
Observational data: associations, not effects.
Safety
- No notable complications
Original publication
Long‐term clinical and radiological outcomes of endoscopic ultrasound‐guided radiofrequency ablation of benign insulinomas. Clin Endocrinol (Oxf). Published 20 October 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →